Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Killikelly, April M ^a   Kanekiyo, Masaru ^a   Graham, Barney S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84990857145     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34108     Document Type: Article

References (26)

1. Graham, B. S. & Anderson, L. J. Challenges and opportunities for respiratory syncytial virus vaccines. Current topics in microbiology and immunology 372, 391-404, doi: 10.1007/978-3-642-38919-1-20 (2013).
2. Meng, J., Stobart, C. C., Hotard, A. L. & Moore, M. L. An Overview of Respiratory Syncytial Virus. Plos Pathog 10, e1004016-1004013 (2014).
3. Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434 (1969).
4. Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff, R. A. & Stewart, C. E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421 (1969).
5. Fulginiti, V. A. et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89, 435-448 (1969).
6. Chin, J., Magoffin, R. L., Shearer, L. A., Schieble, J. H. & Lennette, E. H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89, 449-463 (1969).
7. Murphy, B. R. & Walsh, E. E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. Journal of Clinical Microbiology 26, 1595-1597 (1988).
8. Murphy, B. R. et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 24, 894-898 (1986).
9. Polack, F. P. et al. A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease. The Journal of Experimental Medicine 196, 859-865, doi: 10.1084/jem.20020781 (2002).
10. Knudson, C. J., Hartwig, S. M., Meyerholz, D. K. & Varga, S. M. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. Plos Pathog 11, e1004757 (2015).
11. Wright, P. F. et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25, 7372-7378 (2007).
12. Belshe, R. B., Van Voris, L. P. & Mufson, M. A. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. The Journal of infectious diseases 145, 311-319 (1982).
13. Moghaddam, A. et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nature Medicine 12, 905-907 (2006).
14. Clemens, R. et al. Clinical experience with an inactivated hepatitis A vaccine. The Journal of infectious diseases 171 Suppl 1, S44-S49 (1995).
15. Furesz, J., Scheifele, D. W. & Palkonyay, L. Safety and effectiveness of the new inactivated hepatitis A virus vaccine. CMAJ: Canadian Medical Association Journal 152, 343-348 (1995).
16. Wilton, T., Dunn, G., Eastwood, D., Minor, P. D. & Martin, J. Effect of Formaldehyde Inactivation on Poliovirus. Journal of virology 88, 11955-11964 (2014).
17. McLellan, J. S. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Current Opinion in Virology 11, 70-75 (2015).
18. Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6, 8143 (2015).
19. McLellan, J. S., Yang, Y., Graham, B. S. & Kwong, P. D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. Journal of virology 85, 7788-7796, doi: 10.1128/jvi.00555-11 (2011).
20. Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Science translational medicine 7, 309ra162, doi: 10.1126/scitranslmed.aac4241 (2015).
21. McLellan, J. S. et al. Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. Science 342, 592-598, doi: 10.1126/science.1243283 (2013).
22. Gilman, M. S. A. et al. Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. Plos Pathog 11, e1005035-1005017 (2015).
23. Sanders, R. W. et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, doi: 10.1126/science. aac4223 (2015).
24. Sykes, G. Disinfection and Sterilization. (1965).
25. Nadala, E. C. & Loh, P. C. Dot-blot nitrocellulose enzyme immunoassays for the detection of white-spot virus and yellow-head virus of penaeid shrimp. J. Virol. Methods 84, 175-179 (2000).
26. Chen, M. et al. A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. Journal of Immunological Methods 362, 180-184 (2010).